• SEC Filings

On November 2, 2017, Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), announced its third quarter 2017 financial results. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 2.02. Financial Statements and Exhibits.

(d) Exhibits.

CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 cbio-ex991_70.htm EX-99.1 cbio-ex991_70.htm   Exhibit 99.1 NEWS RELEASE           Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update   — Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end –   — Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end–   SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.